

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO₂ emissions without impacting cost, quality or timelines.

HOW KAYENTIS REDUCES THE CO₂ EMISSIONS OF YOUR eCOA PROJECTS WITH ITS CARBON NEUTRAL PROGRAM

In 2020, we implemented a carbon neutral program for all our clinical trials
Our goal? To reduce project CO₂ emissions without impacting cost, quality or timelines



1 WE EVALUATE THE CARBON FOOTPRINT OF EACH PROJECT

We take into account all CO₂ emissions (scopes 1, 2 & 3) generated during each project (e.g. the production of devices used at clinical sites, the shipping of those devices, and any travel undertaken for project management purposes...) to evaluate the overall carbon impact

2 WE PROPOSE SOLUTIONS TO LIMIT PROJECT CARBON EMISSIONS



ECO-FRIENDLY DEVICE STRATEGY

According to study protocol, we are able to reduce the production, shipping and use of extra devices through:

- A BYOD hybrid strategy
- A WebCOA or Interview mode back-up option
- Refurbished devices / cross-patient reuse of devices within study



OPTIMIZED SHIPPING

To limit the carbon footprint of our shipping, we offer:

- The smallest size shipment boxes possible
- Recyclable cardboard
- Country-level shipments, if possible, to limit number of deliveries



VIRTUAL SUPPORT FOR PATIENTS & SITES

To reduce the carbon footprint of the study-associated travel, we have implemented:

- A Telemedicine app to facilitate study visits while reducing patient travel and supporting decentralized clinical trials
- A resource tool, Kayentis Media Player, available for patients to store training modules, user guides and educational resources



FONDATION
GoodPlanet

3 WE OFFSET RESIDUAL CO₂ EMISSIONS

To go above and beyond, we offset the project carbon emissions that we are unable to reduce by making an equivalent monetary donation to the GoodPlanet Foundation's carbon solidarity action program

This program aims to combat climate change by developing sustainable and economically viable alternatives to polluting activities, to the benefit of the most disadvantaged groups: e.g. construction of solar ovens in Africa, replantation of degraded areas by establishing a sustainable agroforestry model in Ecuador, marine and coastal ecosystem conservation in Mauritius, and forest regeneration in Colombia

Kayentis aims to be a sustainable company in a sustainable world
As such, we support the pharma community's key ambitions to protect the environment

Let us know if you need any more information!




Boston - USA | Meylan - France | Tokyo - Japan



Download the infographic

Ask for more information

Learn more:



How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

31 March 2022

In 2020, we implemented a carbon neutral program for all our clinical trials. Our goal?

[Read More »](#)



Decentralized Clinical Trials

Using a single platform for an enhanced patient experience

31 March 2022

As digitalization of clinical trials accelerates, using a single platform and implementing robust technology integration

[Read More »](#)



Oncology Case Study

25 March 2022

Oncology studies present specific challenges that generate complex eCOA build and management: complex study design,

[Read More »](#)




Kayentis launches fully integrated platform for decentralized clinical trials

23 March 2022

Grenoble, France, March 23, 2022 – Kayentis, a global provider of eCOA and Decentralized Clinical

[Read More »](#)



Interview mode: a valuable data collection alternative supporting Decentralized Clinical Trials

9 March 2022

Collecting ePRO & eObsRO data via interview mode can be recommended in specific circumstances, according

[Read More »](#)



2021 Customer Satisfaction Survey

3 March 2022

90.8% of our clients are likely to recommend Kayentis to a colleague or a friend.

[Read More »](#)